GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » E10

Biogen (HAM:IDP) E10 : €19.52 (As of Jun. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Biogen E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biogen's adjusted earnings per share data for the three months ended in Jun. 2024 was €3.716. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €19.52 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Biogen's average E10 Growth Rate was 1.10% per year. During the past 3 years, the average E10 Growth Rate was 8.60% per year. During the past 5 years, the average E10 Growth Rate was 13.30% per year. During the past 10 years, the average E10 Growth Rate was 20.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Biogen was 186.40% per year. The lowest was -64.80% per year. And the median was 43.20% per year.

As of today (2024-10-29), Biogen's current stock price is €170.90. Biogen's E10 for the quarter that ended in Jun. 2024 was €19.52. Biogen's Shiller PE Ratio of today is 8.76.

During the past 13 years, the highest Shiller PE Ratio of Biogen was 96.15. The lowest was 8.57. And the median was 20.48.


Biogen E10 Historical Data

The historical data trend for Biogen's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen E10 Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.57 13.09 15.88 18.72 18.74

Biogen Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.08 19.72 18.74 19.45 19.52

Competitive Comparison of Biogen's E10

For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Shiller PE Ratio falls into.



Biogen E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=3.716/132.5538*132.5538
=3.716

Current CPI (Jun. 2024) = 132.5538.

Biogen Quarterly Data

per share eps CPI Adj_EPS
201409 2.809 100.428 3.708
201412 3.033 99.070 4.058
201503 3.225 99.621 4.291
201506 3.502 100.684 4.611
201509 3.698 100.392 4.883
201512 3.461 99.792 4.597
201603 3.978 100.470 5.248
201606 4.263 101.688 5.557
201609 4.197 101.861 5.462
201612 2.835 101.863 3.689
201703 3.235 102.862 4.169
201706 3.622 103.349 4.646
201709 4.858 104.136 6.184
201712 -1.191 104.011 -1.518
201803 4.493 105.290 5.656
201806 3.578 106.317 4.461
201809 6.128 106.507 7.627
201812 4.158 105.998 5.200
201903 6.328 107.251 7.821
201906 6.947 108.070 8.521
201909 7.618 108.329 9.322
201912 7.272 108.420 8.891
202003 7.312 108.902 8.900
202006 8.516 108.767 10.378
202009 3.787 109.815 4.571
202012 1.907 109.897 2.300
202103 2.260 111.754 2.681
202106 2.482 114.631 2.870
202109 1.887 115.734 2.161
202112 2.213 117.630 2.494
202203 1.870 121.301 2.043
202206 6.849 125.017 7.262
202209 7.918 125.227 8.381
202212 3.578 125.222 3.787
202303 2.494 127.348 2.596
202306 3.757 128.729 3.869
202309 -0.440 129.860 -0.449
202312 1.568 129.419 1.606
202403 2.484 131.776 2.499
202406 3.716 132.554 3.716

Add all the adjusted EPS together and divide 10 will get our e10.


Biogen  (HAM:IDP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biogen's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=170.90/19.52
=8.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Biogen was 96.15. The lowest was 8.57. And the median was 20.48.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Biogen E10 Related Terms

Thank you for viewing the detailed overview of Biogen's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Headlines

No Headlines